More than 20,000 women are diagnosed with ovarian cancer in the United States each year. Surgery and chemotherapy are generally used to treat ovarian cancer. Despite recent improvements, many women will experience a recurrence of cancer within 3 years.
SC-003 is an antibody drug conjugate in development for ovarian cancer. A Phase 1a clinical trial (NCT02539719) is ongoing and available for enrollment.